Medical AI Alliance
← Company Index
Pharma & CDMOKOSDAQ 09943018 approvals

BioPlus Co., Ltd

Official website

Founded in 2003 and KOSDAQ-listed in 2021, BioPlus develops HA-based bio medical devices and biopharmaceuticals using its proprietary MDM Technology platform.

As of 2026-10-10, BioPlus Co., Ltd has 18 Korean MFDS device approvals on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

BioPlus Co., Ltd was founded in 2003 and listed on KOSDAQ in 2021, developing hyaluronic acid (HA)-based bio medical devices and biopharmaceuticals. Using its proprietary MDM Technology platform (MBMT™, DMCT™, MDAP™), the company manufactures and sells HA fillers such as SkinPlus-Hyal, Bio+Dew and the HyalDew series, the anti-adhesion agent InterBlock, the joint tissue repair material HyalSyno, the bladder tissue repair material Blad-Care, and cosmetics Kiara CE and Kiara Reju. BioPlus received its first HA filler approval from the Ministry of Food and Drug Safety at the end of 2014 and expanded sales from 2015, obtained approval for Blad-Care at the end of 2021, and operates a subsidiary in Hainan, China and a plant in Eumseong, Chungcheongbuk-do, supported by a 25-person R&D organization (3 PhDs, 15 master's, 7 bachelor's).

Products & technology

  • SkinPlus-HyalTemporary improvement of facial wrinkles
  • Bio+DewTemporary improvement of facial wrinkles
  • HyalDew (All/Mid/Fine/Shine)Temporary improvement of facial wrinkles
  • IPCHE PremiumTemporary improvement of facial wrinkles
  • DeneBDermal filler for export
  • InterBlockForms a physical barrier to prevent adhesion between surgical and normal tissue
  • HyalSynoTemporary replacement of synovial fluid lost during knee/shoulder arthroscopic surgery
  • Blad-CareTemporary improvement of cystitis symptoms by supplementing the bladder epithelial GAG layer
  • Kiara CESkin hydration, regeneration promotion and texture improvement
  • Kiara RejuSkin texture improvement using PDRN+HA

Regulatory approvals

data.go.kr

18 Korean MFDS device approvals · 2010–2024

  • MFDSGraft/prosthesis, biomaterial2024-12-11
    Product approval · Class 4제허 24-866 호
  • MFDSGraft/prosthesis, biomaterial2023-05-10
    Product approval · Class 4제허 23-570 호
  • MFDSGraft/prosthesis2023-03-30
    Product approval · Class 4제허 23-456 호
  • MFDSGraft/prosthesis2023-03-30
    Product approval · Class 4제허 23-455 호
  • MFDSGraft/prosthesis, biomaterial2021-11-15
    Product approval · Class 4제허 21-911 호
  • MFDSGraft/prosthesis, biomaterial2021-01-26
    Product approval · Class 4제허 21-64 호
  • MFDSGraft/prosthesis, biomaterial2021-01-05
    Product approval · Class 4제허 21-8 호
  • MFDSGraft/prosthesis, biomaterial2020-09-04
    Product approval · Class 4제허 20-785 호
  • MFDSGraft/prosthesis, biomaterial2020-09-04
    Product approval · Class 4제허 20-784 호
  • MFDSGraft/prosthesis, biomaterial2019-10-29
    Product approval · Class 4제허 19-684 호
  • MFDSGraft/prosthesis, biomaterial2019-03-18
    Product approval · Class 4제허 19-164 호
  • MFDSDressing, adhesion barrier2019-02-01
    Product approval · Class 3제허 19-85 호
Show 6 more
  • MFDSGraft/prosthesis, biomaterial2017-01-03
    Product approval · Class 4제허 17-13 호
  • MFDSDressing, adhesion barrier2016-12-16
    Product approval · Class 3제허 16-965 호
  • MFDSGraft/prosthesis, biomaterial2014-11-19
    Product approval · Class 4제허 14-2316 호
  • MFDS탄력밴드Revoked2012-09-03
    Product approval · Class 1서울 수신 12-1775 호
  • MFDS탄력밴드Revoked2011-08-23
    Product approval · Class 1서울 수신 11-1499 호
  • MFDSGraft/prosthesis, biomaterial2010-08-27
    Product approval · Class 4제허 10-865 호

Global clinical trials

ClinicalTrials.gov · sponsor-matched

R&D and key agreements

Source: DART corporate disclosure

차세대 보툴리눔 톡신 · 미용 및 만성 질환 치료 · Co-developing next-generation botulinum toxin material with reduced side effects and improved stability with Ubiprotein and ProCell Therapeutics (Mar 2022, Aug 2022)

비만/당뇨 치료제 · 비만, 당뇨 · Developing bulk production of GLP-1 class raw materials (Liraglutide, Semaglutide) with Pepgene technology (Jan 2025) and an improved dosage form using SNTel's micro-needle patch technology (Jan 2025)

아토피치료용 의약품 · 아토피 · Co-development with Centrics Bio (Jun 2023)

치매 치료제 위탁연구 · 치매 · Contract research for Centrics Bio's national dementia-treatment project, developing and optimizing the mass production process (Jun 2023)

Key disclosures

KRX KIND via OpenDART

Patents

KIPRIS · applicant-matched
Show 8 more patents

AI reads

MAA server logs · IP-verified
123
Times AI engines pulled BioPlus Co., Ltd's records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

2
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

121
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

11
live 0
Last 7 days
98
live 1
Last 30 days
123
live 2
All time
  • OpenAIChatGPT-Userlive2
  • OpenAIOAI-SearchBot100
  • GoogleGoogleOther10
  • PerplexityPerplexityBot8
  • AnthropicClaudeBot2
  • MicrosoftBingbot1

Measured since Aug 27, 2026 · 5 AI engines · last read Oct 9, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for BioPlus Co., Ltd and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview. Send us materials and we will add them

Companies approved for the same productsPharma & CDMO

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

BNC KOREA, Inc.6 shared

Founded and listed on the KOSDAQ in 2016, BNC Korea is a biohealthcare company specializing in HA fillers, botulinum toxin, and dermo-cosmetics.

JETEMA Co.,Ltd.4 shared

Founded 2009, listed on KOSDAQ in 2019, JETEMA develops hyaluronic acid fillers, botulinum toxin biopharmaceuticals, and lifting threads.

DongBang Medical Co., Ltd.3 shared

KOSDAQ-listed medical device maker producing disposable acupuncture needles, cupping cups, and hyaluronic acid dermal fillers.

Chabiotech Co.,Ltd.3 shared

Cord blood storage and cell therapy company that has expanded into global CDMO manufacturing and overseas medical network services.

PharmaResearch Co., Ltd.3 shared

KOSDAQ-listed medical device company producing PDRN pharmaceuticals, HA fillers, and Rejuran-branded cosmetics.

DongKookPharmaceuticalCo.,Ltd.3 shared

KOSDAQ-listed comprehensive healthcare and pharmaceutical company behind the gum treatment Insadol and the wound-care ointment Madecassol.

Hanmi Science Co.,Ltd2 shared

KOSPI-listed operating holding company of the Hanmi Pharm group, also running healthcare and pharmaceutical wholesale businesses.

BIOBIJOU Co., Ltd.2 shared

KOSDAQ-listed aesthetics exporter behind HA skin booster CANDOLOV SERUM and filler brands COLENA and CANDORLOV.

Medy-Tox Inc.2 shared

Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.

METABIOMED.CO.,LTD2 shared

KOSDAQ-listed medical device company manufacturing synthetic bioresorbable suture yarn and dental root canal filling materials.

Humedix Co., Ltd.2 shared

KOSDAQ-listed aesthetics and CMO company behind the Elravie/Revolax hyaluronic-acid fillers and Leedstox botulinum toxin.

CAREGEN CO.,LTD.2 shared

CAREGEN develops peptide-based cosmeceuticals sold in 130 countries and ophthalmic drug candidates CG-P5 and CG-T1.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition